Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885469 · ClinicalTrials.gov registry record
PillCam® ESO 2 in Esophageal Pathologies
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 101
- Enrollment target
NCT00885469: Completed study, sponsored by Medtronic - MITG.
NCT00885469 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00885469 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
Study Hypothesis: * PillCam™ ESO-2 will demonstrate equivalent accuracy parameters as compared to blinded esophagogastroduodenoscopy (EGD) in detecting suspected Barrett's esophagus, detecting and grading esophagitis. * PillCam™ ESO will demonstrate all safety parameters as compared to EGD * PillCam™ ESO-2 will demonstrate better patient's satisfaction as compared to EGD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-04 |
What the finished NCT00885469 record still lists
NCT00885469 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00885469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00885469 about?
NCT00885469 is a clinical study titled "PillCam® ESO 2 in Esophageal Pathologies". Study Hypothesis: * PillCam™ ESO-2 will demonstrate equivalent accuracy parameters as compared to blinded esophagogastroduodenoscopy (EGD) in detecting suspected Barrett's esophagus, detecting and grading esophagitis. * PillCam™ ESO will demonstrate all safety parameters as compared to EGD * PillCa...
What is the current status of trial NCT00885469?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2007-12. Estimated completion is 2009-04.
Who is sponsoring clinical trial NCT00885469?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia